Immunogenicity and tolerogenicity of hepatitis B virus structural and nonstructural proteins: Implications for immunotherapy of persistent viral infections

被引:111
作者
Kakimi, K
Isogawa, M
Chung, JS
Sette, A
Chisari, FV
机构
[1] Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA
[2] Epimmune Inc, San Diego, CA 92121 USA
[3] Tokyo Med Univ, Dept Internal Med 4, Tokyo 1600023, Japan
关键词
D O I
10.1128/JVI.76.17.8609-8620.2002
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Persistent hepatitis B virus (HBV) infection is characterized by a weak and narrowly focused CD8(+) T-cell response to HBV that is thought to reflect the induction of central and/or peripheral tolerance to HBV proteins in neonatal and adult onset infections, respectively. Immunotherapeutic strategies that overcome tolerance and boost these suboptimal responses may lead to viral clearance in chronically infected individuals. The present study was performed to compare the relative immunogenicities and tolerogenicities of HBV structural (envelope [ENV]) and nonstructural (polymerase [POL]) proteins at the CD8(+) cytotoxic T lymphocyte (CTL) level in transgenic mice that replicate HBV in the liver and secrete infectious virus into the blood, thus representing an excellent model of persistent HBV infection. Interestingly, the mice were tolerant to the ENV but not to the POL proteins at the CTL level. Furthermore, the POL-specific CTLs had no impact on HBV replication or liver function in vivo, even though they were readily induced and reached the liver after DNA immunization, reflecting their relatively low avidity and the low level at which the POL protein is expressed by the hepatocyte. Collectively, these results suggest that the factors that make POL less tolerogenic also make POL-specific CTLs relatively inefficient effector cells when they reach the target organ. Immunotherapeutic strategies to control HBV infection by inducing virus-specific CTL responses in chronically infected subjects should be evaluated in light of this observation.
引用
收藏
页码:8609 / 8620
页数:12
相关论文
共 37 条
[1]  
ALWAN WH, 1993, J IMMUNOL, V150, P5211
[2]   MECHANISMS OF CLASS-I RESTRICTED IMMUNOPATHOLOGY - A TRANSGENIC MOUSE MODEL OF FULMINANT-HEPATITIS [J].
ANDO, K ;
MORIYAMA, T ;
GUIDOTTI, LG ;
WIRTH, S ;
SCHREIBER, RD ;
SCHLICHT, HJ ;
HUANG, SN ;
CHISARI, FV .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (05) :1541-1554
[3]  
ANDO K, 1994, J IMMUNOL, V152, P3245
[4]   HLA CLASS-I-RESTRICTED HUMAN CYTOTOXIC T-CELLS RECOGNIZE ENDOGENOUSLY SYNTHESIZED HEPATITIS-B VIRUS NUCLEOCAPSID ANTIGEN [J].
BERTOLETTI, A ;
FERRARI, C ;
FIACCADORI, F ;
PENNA, A ;
MARGOLSKEE, R ;
SCHLICHT, HJ ;
FOWLER, P ;
GUILHOT, S ;
CHISARI, FV .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (23) :10445-10449
[5]   DEFINITION OF A MINIMAL OPTIMAL CYTOTOXIC T-CELL EPITOPE WITHIN THE HEPATITIS-B VIRUS NUCLEOCAPSID PROTEIN [J].
BERTOLETTI, A ;
CHISARI, FV ;
PENNA, A ;
GUILHOT, S ;
GALATI, L ;
MISSALE, G ;
FOWLER, P ;
SCHLICHT, HJ ;
VITIELLO, A ;
CHESNUT, RC ;
FIACCADORI, F ;
FERRARI, C .
JOURNAL OF VIROLOGY, 1993, 67 (04) :2376-2380
[6]   Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B [J].
Boni, C ;
Bertoletti, A ;
Penna, A ;
Cavalli, A ;
Pilli, M ;
Urbani, S ;
Scognamiglio, P ;
Boehme, R ;
Panebianco, R ;
Fiaccadori, F ;
Ferrari, C .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 102 (05) :968-975
[7]   VACCINIA VIRUS EXPRESSION VECTOR - COEXPRESSION OF BETA-GALACTOSIDASE PROVIDES VISUAL SCREENING OF RECOMBINANT VIRUS PLAQUES [J].
CHAKRABARTI, S ;
BRECHLING, K ;
MOSS, B .
MOLECULAR AND CELLULAR BIOLOGY, 1985, 5 (12) :3403-3409
[8]   HEPATITIS-B VIRUS IMMUNOPATHOGENESIS [J].
CHISARI, FV ;
FERRARI, C .
ANNUAL REVIEW OF IMMUNOLOGY, 1995, 13 :29-60
[9]   Viruses, immunity, and cancer: Lessons from hepatitis B [J].
Chisari, FV .
AMERICAN JOURNAL OF PATHOLOGY, 2000, 156 (04) :1117-1132
[10]   DNA-MEDIATED IMMUNIZATION IN MICE INDUCES A POTENT MHC CLASS I-RESTRICTED CYTOTOXIC T-LYMPHOCYTE RESPONSE TO THE HEPATITIS-B ENVELOPE PROTEIN [J].
DAVIS, HL ;
SCHIRMBECK, R ;
REIMANN, J ;
WHALEN, RG .
HUMAN GENE THERAPY, 1995, 6 (11) :1447-1456